EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
University Hospital Heidelberg
Heidelberg, AlemaniaPublicaciones en colaboración con investigadores/as de University Hospital Heidelberg (5)
2020
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 21, Núm. 4, pp. 519-530
2015
-
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial
The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710
-
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
New England Journal of Medicine, Vol. 372, Núm. 8, pp. 724-734
2013
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology, Vol. 14, Núm. 6, pp. 461-471
-
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
Journal of Clinical Oncology, Vol. 31, Núm. 20, pp. 2586-2592